Carlos Plaza
Research Subjects
Carlos Plaza has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andres Orquera
Hematology Service, Carlos Andrade Marín Hospital, Quito, Ecuador
1 shared publication - Brenner Sabando
IRHED Medical Specialties Center Guayaquil Ecuador
1 shared publication - Danilo Navarrete
Hemato-Oncology and Medicine Transfusion Department, Solca Cancer Institute, Manabi, Ecuador
1 shared publication Jairo Quinonez
Department of Hematology, IRHED Medical Specialties Center, Guayaquil, Ecuador
1 shared publication- Jhoanna Ramirez
Hematology Service, Teodoro Maldonado Carbo Hospital, Guayaquil, Ecuador
1 shared publication - Jorge Oliveros
Hematology Service, Luis Vernaza Hospital, Guayaquil, Ecuador
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Advances in Hematology
- Vol. 2025 (1)
Hyper‐CVAD in Adults With Acute Lymphoblastic Leukemia in Ecuador: A Multicenter Retrospective Study
Background: The Hyper‐CVAD protocol is a chemotherapy regimen widely used in hematological malignancies. It is considered one of most promising remission‐leading treatment option for adults with acute lymphoblastic leukemia (ALL). Objective: To determine the outcomes of adults with ALL treated with the Hyper‐CVAD protocol in Ecuador. Methods: This multicenter, retrospective, cross‐sectional study compared the outcomes of ALL patients aged 15 years and older treated with hyper‐CVAD protocol in 8 specialized centers. Results: 139 patients with ALL treated with the Hyper‐CVAD protocol were included. A total of 79 were female (56.8%) and the majority had a B‐type phenotype 130 (93.5%). A complete response (CR) was achieved in 64.3%. Relapse was confirmed in 52.7% of those who obtained CR. Negative minimal residual disease (MRD) was achieved in 20% of patients. The median overall survival (OS) was 11 months (95% CI: 7.49–14.50) with a 5‐year OS of 14.0%. A total of 12 (8.6%) deceased during induction phase. Conclusion: Adult patients treated with the Hyper‐CVAD protocol in Ecuador achieve rates of CR, MRD, and OS lower than those presented in international cohorts, as well as higher rates of treatment‐related toxicity.
- 1 January 2025
- Published by Wiley in Advances in Hematology
- Vol. 2025 (1)
Open AccessHyper‐CVAD in Adults With Acute Lymphoblastic Leukemia in Ecuador: A Multicenter Retrospective Study
Background: The Hyper‐CVAD protocol is a chemotherapy regimen widely used in hematological malignancies. It is considered one of most promising remission‐leading treatment option for adults with acute lymphoblastic leukemia (ALL). Objective: To determine the outcomes of adults with ALL treated with the Hyper‐CVAD protocol in Ecuador. Methods: This multicenter, retrospective, cross‐sectional study compared the outcomes of ALL patients aged 15 years and older treated with hyper‐CVAD protocol in 8 specialized centers. Results: 139 patients with ALL treated with the Hyper‐CVAD protocol were included. A total of 79 were female (56.8%) and the majority had a B‐type phenotype 130 (93.5%). A complete response (CR) was achieved in 64.3%. Relapse was confirmed in 52.7% of those who obtained CR. Negative minimal residual disease (MRD) was achieved in 20% of patients. The median overall survival (OS) was 11 months (95% CI: 7.49–14.50) with a 5‐year OS of 14.0%. A total of 12 (8.6%) deceased during induction phase. Conclusion: Adult patients treated with the Hyper‐CVAD protocol in Ecuador achieve rates of CR, MRD, and OS lower than those presented in international cohorts, as well as higher rates of treatment‐related toxicity.